Federal Register #HHS-ASPE-2026-0298

HHS RFI on Alzheimer's Plan and NEI PEDF Peptide Therapeutic License Opportunity

This opportunity involves two distinct initiatives from the U.S. Department of Health and Human Services (HHS):

• Request for Information (RFI) on the National Plan to Address Alzheimer's Disease

  • HHS seeks public input to inform the update of the National Plan, guiding federal efforts through 2035.
  • Focus areas include advancing research, developing new interventions, risk reduction, early detection, diagnostics, care, and coordination for Alzheimer's disease and related dementias.
  • No products or services are being procured; this is a request for comments and suggestions from stakeholders.

• National Eye Institute (NEI) License Opportunity: PEDF Peptide Therapeutic

  • NEI offers a license for a Pigment Epithelium-Derived Factor (PEDF) peptide therapeutic, delivered via AAV2 vector or eyedrop.
  • The therapeutic targets inherited retinal diseases such as retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy, Stargardt-like macular degeneration, and age-related macular degeneration.
  • The PEDF peptide therapeutic is in pre-clinical development and is not yet commercially available.
  • No specific OEMs or commercial vendors are named; the opportunity is for licensing the technology.

Notable Details: - The PEDF peptide therapeutic (part number E0282023) is a novel treatment in early-stage development, available for licensing to interested parties. - The RFI does not involve procurement or contracting for goods or services.

Description

The Department of Health and Human Services (HHS) is seeking public input to inform the update of the National Plan to Address Alzheimer's Disease through 2035. The plan guides federal efforts in research, care, public health, and data infrastructure related to Alzheimer's disease and related dementias (AD/ADRD). HHS invites comments on advancing research, developing new interventions, risk reduction strategies, early detection and diagnostics, enhanced care and services, and coordination opportunities. The input will help shape future goals and priorities for the national Alzheimer's plan.

View original listing